Home
ACET
ACET News

Latest Adicet Bio Inc. (ACET) News on November 28, 2025

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

GlobeNewswire

15 days ago

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Business Wire

22 days ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Business Wire

a month ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a month ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Business Wire

a month ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?

Business Wire

2 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Business Wire

2 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Business Wire

6 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Business Wire

7 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Business Wire

7 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Business Wire

7 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Simply Wall St.

7 months ago

We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Business Wire

7 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Business Wire

8 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire

8 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts

Insider Monkey

8 months ago

Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts

Business Wire

9 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Business Wire

9 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Investing.com

9 months ago

Adicet Bio shares rise on FDA Fast Track Designation for ADI-001

Business Wire

9 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Business Wire

10 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Business Wire

10 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Business Wire

a year ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Business Wire

a year ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Business Wire

a year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Business Wire

a year ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Business Wire

a year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Business Wire

a year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a year ago

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Business Wire

a year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Business Wire

a year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Business Wire

a year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio to Participate in Upcoming Investor Conferences

Business Wire

a year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Business Wire

a year ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials

TipRanks

a year ago

Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials

Business Wire

a year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Business Wire

a year ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Business Wire

a year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Business Wire

a year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Business Wire

a year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Business Wire

a year ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire

a year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Business Wire

a year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Business Wire

a year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Participate in Upcoming Investor Conferences

Business Wire

a year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds?

Insider Monkey

a year ago

Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds?

Owning 44% shares,institutional owners seem interested in Adicet Bio, Inc. (NASDAQ:ACET),

Simply Wall St.

a year ago

Owning 44% shares,institutional owners seem interested in Adicet Bio, Inc. (NASDAQ:ACET),

Business Wire

a year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Business Wire

a year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ?

Insider Monkey

a year ago

Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ?

We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Simply Wall St.

a year ago

We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Business Wire

a year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Business Wire

a year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Business Wire

2 years ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Business Wire

2 years ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Business Wire

2 years ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 years ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Business Wire

2 years ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire

2 years ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 years ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?

Simply Wall St.

2 years ago

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Business Wire

2 years ago

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Business Wire

2 years ago

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 years ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Business Wire

2 years ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 years ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Business Wire

2 years ago

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Adicet Bio, Inc. Announces Pricing of Public Offering

Business Wire

2 years ago

Adicet Bio, Inc. Announces Pricing of Public Offering

Adicet Bio, Inc. Announces Proposed Public Offering

Business Wire

2 years ago

Adicet Bio, Inc. Announces Proposed Public Offering

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

Zacks

2 years ago

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

Sify reports Consolidated Financial Results for Q3 FY 2023-24

GlobeNewswire

2 years ago

Sify reports Consolidated Financial Results for Q3 FY 2023-24

Everspin Technologies, Inc.'s (NASDAQ:MRAM) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Simply Wall St.

2 years ago

Everspin Technologies, Inc.'s (NASDAQ:MRAM) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Great week for Adicet Bio, Inc. (NASDAQ:ACET) institutional investors after losing 71% over the previous year

Simply Wall St.

2 years ago

Great week for Adicet Bio, Inc. (NASDAQ:ACET) institutional investors after losing 71% over the previous year

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Business Wire

2 years ago

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Business Wire

2 years ago

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

THE MEXICO FUND, INC. ISSUES ITS 2023 ANNUAL REPORT

PR Newswire

2 years ago

THE MEXICO FUND, INC. ISSUES ITS 2023 ANNUAL REPORT

Jiayin Group Inc. Announces Change of Auditor

GlobeNewswire

2 years ago

Jiayin Group Inc. Announces Change of Auditor

Reuters

2 years ago

African online retailer Jumia to cease food delivery business

Jumia to Focus on Physical Goods Business and Close its Food Delivery Operations

ACCESSWIRE

2 years ago

Jumia to Focus on Physical Goods Business and Close its Food Delivery Operations

Business Wire

2 years ago

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?

Zacks

2 years ago

Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?

GlobeNewswire

2 years ago

David Kanen, president of Kwm llc issues letter to the eGain board calling for the formation of a special committee and sale of egan. He also excoriates CEO Ashu Roy.

Duluth Holdings (DLTH) Reports Q3 Loss, Misses Revenue Estimates

Zacks

2 years ago

Duluth Holdings (DLTH) Reports Q3 Loss, Misses Revenue Estimates

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

Perimeter Solutions Reports Third Quarter 2023 Financial Results

Newsfile

2 years ago

Perimeter Solutions Reports Third Quarter 2023 Financial Results

Share on Social Networks: